Cargando…

Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab

The primary tumour location is an important prognostic factor for previously untreated metastatic colorectal cancer (mCRC). However, the predictive efficacies of primary tumour location, early tumour shrinkage (ETS), and depth of response (DpR) on mCRC treatment has not been fully evaluated. This st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sagawa, Tamotsu, Sato, Yasushi, Hirakawa, Masahiro, Hamaguchi, Kyoko, Fukuya, Akira, Okamoto, Koichi, Miyamoto, Hiroshi, Muguruma, Naoki, Fujikawa, Koshi, Takahashi, Yasuo, Takayama, Tetsuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666202/ https://www.ncbi.nlm.nih.gov/pubmed/33188279 http://dx.doi.org/10.1038/s41598-020-76756-1

Ejemplares similares

Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer
por: Sagawa, Tamotsu, et al.
Publicado: (2023)

Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report
por: Sagawa, Tamotsu, et al.
Publicado: (2023)

Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
por: Takada, Shinya, et al.
Publicado: (2018)

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours
por: Yonemori, Kan, et al.
Publicado: (2016)

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
por: Saka, Hideo, et al.
Publicado: (2017)

Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives
por: Sato, Yasushi, et al.
Publicado: (2023)

Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways
por: Greening, David W., et al.
Publicado: (2015)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
por: Tomonari, Tetsu, et al.
Publicado: (2022)

DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6
por: O'Connor, J P B, et al.
Publicado: (2011)

Correction: Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways
por: Greening, David W., et al.
Publicado: (2016)

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study
por: Brandes, Alba A., et al.
Publicado: (2017)

Endoscopic Molecular Imaging: Status and Future Perspective
por: Muguruma, Naoki, et al.
Publicado: (2013)

A Novel Theranostic Combination of Near-infrared Fluorescence Imaging and Laser Irradiation Targeting c-KIT for Gastrointestinal Stromal Tumors
por: Fujimoto, Shota, et al.
Publicado: (2018)

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma
por: Kondo, T, et al.
Publicado: (2016)

Variation of Shrinkage Strain within the Depth of Concrete Beams
por: Jeong, Jong-Hyun, et al.
Publicado: (2015)

Endoscopic Management of Nonvariceal Upper Gastrointestinal Bleeding: State of the Art
por: Muguruma, Naoki, et al.
Publicado: (2015)

EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model
por: Gustafsson, H., et al.
Publicado: (2017)

A case of cetuximab-related tumour lysis syndrome in metastatic rectal carcinoma
por: Haroon, Muhammad, et al.
Publicado: (2010)

Twin Rectal Tonsils Mimicking Carcinoid or Mucosa-Associated Lymphoid Tissue Lymphoma
por: Takehara, Masanori, et al.
Publicado: (2017)

Narrow Band Imaging as an Efficient and Economical Tool in Diagnosing Colorectal Polyps
por: Muguruma, Naoki, et al.
Publicado: (2015)

Endoscopic Sclerotherapy with Aluminum Potassium Sulfate and Tannic Acid: An Effective and Less Invasive Strategy for Internal Hemorrhoids
por: Muguruma, Naoki, et al.
Publicado: (2019)

Artificial Intelligence-Based Colorectal Polyp Histology Prediction: High Accuracy in Larger Polyps
por: Muguruma, Naoki, et al.
Publicado: (2022)

Detection of aberrant crypt foci with image-enhanced endoscopy
por: Kagemoto, Kaizo, et al.
Publicado: (2018)

Epidermal growth factor receptor‐targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models
por: Miyamoto, Yoshihiko, et al.
Publicado: (2019)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada
por: Drucker, A., et al.
Publicado: (2008)

Regulatory T Cells but Not Tumour-Infiltrating Lymphocytes Correlate with Tumour Invasion Depth in Basal Cell Carcinoma
por: Ferronika, Paranita, et al.
Publicado: (2022)

Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma
por: Takehara, Masanori, et al.
Publicado: (2021)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021)

Resveratrol inhibits development of colorectal adenoma via suppression of LEF1; comprehensive analysis with connectivity map
por: Wada, Hironori, et al.
Publicado: (2022)

Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives
por: Sato, Yasushi, et al.
Publicado: (2022)

Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
por: Köhne, Claus-Henning, et al.
Publicado: (2019)

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer
por: Bottini, A, et al.
Publicado: (2001)

The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected
por: Wason, James MS, et al.
Publicado: (2015)

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials
por: Taieb, Julien, et al.
Publicado: (2017)

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
por: Dudek, A Z, et al.
Publicado: (2009)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach
por: Yoshii, M, et al.
Publicado: (2012)

Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t7h8ks1jdkr3932qd30sj8b02h